Our Pipeline

The Company’s SYMJEPI® (epinephrine) Injection is approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI® (naloxone) Injection is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial has been conducted.

POTENTIAL INDICATION1 PHASE 1 PHASE 2 PHASE 3 NDA APPROVED
SYMJEPI® (epinephrine)2 Injection 0.3mg Anaphylaxis
SYMJEPI® (epinephrine)2 Injection 0.15mg Anaphylaxis
ZIMHI® (naloxone)2 Injection 5mg Opioid Overdose
APC-400 (tempol) Oral Capsule/Tablet Respiratory Disease / Anti Inflammatory
1 Represents the next development/regulatory stage Adamis intends to pursue 2 Licensed U.S. commercial rights to US WorldMeds

Areas of Focus: Allergy, Respiratory and Opioid overdose

SYMJEPI® (epinephrine)
ZIMHI®(naloxone)
APC-400 (tempol) – Capsule